Background: An autologous stem cell transplant is an established treatment option for patients with Multiple Myeloma. Many centers treat these patients and have transplantation capabilities but due to the high cost and lack of technical expertise lack of cryopreservation facilities for processing and preserving cells. Methods: This retrospective study was conducted in IMS __ampersandsignamp; SUM Hospital, Bhubaneswar, Odisha from August 2019 to January 2020 in which all the five cases of multiple myeloma which were eligible for stem cell transplant were included. Three stem cell transplants were performed in the COBE spectra auto PBSC system (Terumo BCT, Lakewood, CO) and rest two were performed in the Spectra Optia Apheresis system. Analysis of various characteristics like gender, age, weight, disease status, regimen used, pre-procedure total leukocyte count, pre-procedure CD34 positive cells count, pre-procedure absolute CD34+ cell count, mobilization regimen, time of harvest, and processed apheresis volume was done. All patients were followed until their engraftment and discharge. Results: The number of days of stem cell harvest was 5th and 6th day. The median CD34 cell dose was 47.2/cells/__ampersandsignmicro;l. In all cases CD34 count in bag __ampersandsigngt; 5 x 106/ kg .The median time to neutrophil engraftment was 10th day and platelet engraftment was 11th day in all cases. There were no adverse reactions during HPC transfusion. All patients were doing well till date. Conclusion: Autologous Hematopoietic Stem Cell Transplant without cryopreservation resulted in adequate engraftment. Proper planning and coordination between clinicians and Transfusion Medicine specialist are a basic fundamental for efficient transplant and the best possible outcome.